Truant Stéphanie, Séquier Cédric, Leteurtre Emmanuelle, Boleslawski Emmanuel, Elamrani Mehdi, Huet Guillemette, Duhamel Alain, Hebbar Mohamed, Pruvot François-René
Department of Digestive Surgery and Transplantation, Lille University Medical Center, University of Lille Nord de France, Lille, France.
HPB (Oxford). 2015 Feb;17(2):176-84. doi: 10.1111/hpb.12316. Epub 2014 Jul 9.
The aim of the authors was to reassess the impact of a positive surgical margin (R1) after a liver resection for colorectal liver metastases (CLMs) on survival in the era of modern chemotherapy, through their own experience and a literature review.
Inclusion criteria were: R1 or R0 resection with no local treatment modalities, extra-hepatic metastases or other cancer.
Among 337 patients operated between 2000 and 2010, 273 patients were eligible (214 R0/59 R1). The mean follow-up was 43 ± 29 months. Compared with a R0 resection, a R1 resection offered a lower 5-year overall (39.1% versus 54.2%, P = 0.010), disease-free (15.2% versus 31.1%, P = 0.021) and progression-free (i.e. time to the first non-curable recurrence; 33.1% versus 47.3%, P = 0.033) survival rates. Metastases in the R1 group were more numerous, larger and more frequently synchronous. Independent factors of poor survival were: number, size and short-time interval of CLM occurrence, N status, rectal primary, absence of adjuvant chemotherapy, but not a R1 resection. With the more-systematic administration of chemotherapy since 2005, the intergroup difference in progression-free survival disappeared (P = 0.264).
A R1 resection had no prognostic value per se but reflected a more severe disease. The recent change in the prognostic value of a R1 resection may be linked to the beneficial effect of chemotherapy.
作者旨在通过自身经验及文献回顾,重新评估在现代化疗时代,结直肠癌肝转移(CLM)肝切除术后切缘阳性(R1)对生存的影响。
纳入标准为:行R1或R0切除,未采用局部治疗方式,无肝外转移或其他癌症。
2000年至2010年间接受手术的337例患者中,273例符合条件(214例R0/59例R1)。平均随访时间为43±29个月。与R0切除相比,R1切除的5年总生存率(39.1%对54.2%,P = 0.010)、无病生存率(15.2%对31.1%,P = 0.021)和无进展生存率(即首次不可治愈复发的时间;33.1%对47.3%,P = 0.033)较低。R1组的转移灶更多、更大且更常为同时性。生存不良的独立因素为:CLM发生的数量、大小和短时间间隔、N分期、直肠原发癌、未行辅助化疗,但不包括R1切除。自2005年以来化疗应用更为系统,组间无进展生存率差异消失(P = 0.264)。
R1切除本身无预后价值,但反映了病情更严重。R1切除预后价值的近期变化可能与化疗的有益作用有关。